Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 4/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814511 | 0.84 | NPSR1 (0.59) | NPSR1KMT2ALMNAHTTCNR1 | |
| SCHEMBL6323283 | 0.76 | NPSR1 (0.51) | NPSR1KMT2ALMNAHTTCNR1 | |
| SCHEMBL28280894 | 0.75 | NPSR1 (0.56) | NPSR1KMT2AMAPK9MAPK10KCNH2 | |
| SCHEMBL4811912 | 0.74 | CNR1 (0.44) | KMT2ACNR1CNR2 | |
| SCHEMBL4802735 | 0.71 | CNR1 (0.41) | KMT2ACNR1CNR2 | |
| SCHEMBL4806722 | 0.70 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL22672408 | 0.68 | NPSR1 (1.00) | NPSR1KMT2ALMNAHTTCNR1 | |
| SCHEMBL4811618 | 0.67 | ALDH1A1 (0.39) | LMNACNR1CNR2 | |
| SCHEMBL30722321 | 0.64 | FGFR4 (0.43) | NPSR1CNR1CNR2 | |
| SCHEMBL10012834 | 0.64 | NPSR1 (0.44) | NPSR1KMT2AHTTMAPK10KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245554-A1 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245554-A1 | Substituted pyrimidines | CNR1, CNR2, GPR119 | NPSR1 21/4885KMT2A 3592/4885LMNA 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.